Belluscura PLC Directorate Change
11 Julio 2024 - 5:30AM
RNS Regulatory News
RNS Number : 0625W
Belluscura PLC
11 July 2024
11 July 2024
BELLUSCURA PLC
("Belluscura" or the
"Company")
Directorate Change
Belluscura plc (AIM: BELL), a leading medical device developer focused on
lightweight and portable oxygen enrichment technology, announces
that Jonathan Satchell, Non-executive Director, has informed the
Board that he intends to step down from his role as a Non-executive
Director with effect from 11 July 2024.
Jonathan was appointed to the Board
in February 2024 following the acquisition of TMT Acquisition plc
by the Company.
Adam Reynolds, Chairman of Belluscura,
commented:
"On behalf of the Board, I would
like to thank Jonathan for his valued contribution during his time
on the Board of Belluscura. His insights and advice have been
greatly appreciated since he joined the Board following the
Company's acquisition of TMT Acquisition plc and we wish him well
with his other roles."
-Ends-
For further information please
contact:
Belluscura plc
|
Tel: +44
(0)20 3128 8100
|
Adam Reynolds, Chairman
|
|
|
|
SPARK Advisory Partners Limited
Nominated Adviser
|
Tel: +44
(0)20 3368 3550
|
Neil Baldwin / Jade Bayat
|
|
|
|
Dowgate Capital Limited
Broker
|
Tel: +44
(0)20 3903 7715
|
Russell Cook / Nicholas
Chambers
|
|
|
|
MHP
Financial PR & Investor Relations
|
Tel: +44
(0)20 3128 8100
email:
Belluscura@mhpgroup.com
|
Katie Hunt/Matthew Taylor
|
|
About Belluscura plc
(https://belluscura.com/)
Belluscura is a UK medical device
company focused on developing oxygen enrichment technology spanning
broad industries and therapies. Our innovative oxygen technologies
are designed with a global purpose: to create improved health and
economic outcomes for the patients, healthcare providers and
insurance organisations.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BOAQKDBDKBKDBOD
Belluscura (LSE:BELL)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Belluscura (LSE:BELL)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024